ORIC-944
- Generic Name
- ORIC-944
Study of ORIC-944 in Patients With Metastatic Prostate Cancer
Phase 1
Recruiting
- Conditions
- Metastatic Prostate Cancer
- Interventions
- First Posted Date
- 2022-06-10
- Last Posted Date
- 2025-03-20
- Lead Sponsor
- ORIC Pharmaceuticals
- Target Recruit Count
- 42
- Registration Number
- NCT05413421
- Locations
- 🇺🇸
South Florida Oncology and Hematology, Plantation, Florida, United States
🇺🇸First Urology, Jeffersonville, Indiana, United States
🇺🇸University of Washington, Fred Hutchinson Cancer Center, Seattle, Washington, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath